SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

ANG Lifesciences India informs about updates

13 Sep 2021 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ANG Lifesciences India has informed that the company has already crossed 200 cr revenue milestone and going forward, the company is expecting similar robust growth in coming quarters. The Company is expected to post turnover around Rs 400-450 cr. with expected IT in measurable terms Rs 15 cr approx in F.Y. 2021-22. Also, the Company has been able to show handsome growth backed by persistent and focused efforts by the management in its goal of maintaining the growth trend on going forward.

The above information is a part of company’s filings submitted to BSE.

ANG Lifesciences Share Price

26.84 0.00 (0.00%)
22-Apr-2026 09:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1662.00
Dr. Reddys Lab 1212.00
Cipla 1225.30
Zydus Lifesciences 925.00
Lupin 2290.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×